ANP (Atrial Natriuretic Peptide) vs Humanin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | Humanin |
|---|---|---|
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. |
| Best For |